Institute for Myeloma & Bone Cancer Research

Recent papers from Institute for Myeloma & Bone Cancer Research

1. Angiotensin-converting enzyme overexpression in mouse neutrophils prevents Alzheimer’s-like cognitive declineFrontiers in Immunology · 2026
2. Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growthSignal Transduction and Targeted Therapy · 2026
3. A-141 Biological variation of soluble B-cell maturation antigen in healthy donorsClinical Chemistry · 2025
4. Serum B‐Cell Maturation Antigen as a Biomarker for Predicting Outcomes and Monitoring Patients With Waldenström MacroglobulinemiaEuropean Journal Of Haematology · 2025
5. Shared clinical and immunologic features of mRNA vaccines: preliminary results from a comparative clinical studyFrontiers in Immunology · 2025
6. Shared Clinical and Immunologic Features of mRNA Vaccines: Preliminary Results from a Comparative Clinical Study2024
7. Medical writing bias in myeloma clinical research: A comprehensive analysisPerspectives in Clinical Research · 2024
8. Serum B-Cell Maturation Antigen Reflects Disease Status in a Patient Who Developed Nonsecretory Multiple Myeloma: A Case ReportCase Reports in Oncology · 2024
9. Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myelomaOncotarget · 2024
10. Targeting B-cell maturation antigen for treatment and monitoring of relapsed/refractory multiple myeloma patients: a comprehensive reviewTherapeutic Advances in Hematology · 2024
11. Efficacy of isatuximab in combination with steroids for the treatment of relapsed/refractory multiple myeloma patients exhibiting only biochemical progression—A single center retrospective studyEuropean Journal Of Haematology · 2023
12. Third dose of an mRNA COVID-19 vaccine for patients with multiple myelomaClinical Infection in Practice · 2022
13. Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myelomaBritish Journal of Haematology · 2022
14. Efficacy of venetoclax plus anti‐CD38 monoclonal antibody‐containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibodyEuropean Journal Of Haematology · 2022
15. A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patientsHematological Oncology · 2022
16. Use of serum B‐cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisoloneHematological Oncology · 2022
17. Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccinationClinical Infection in Practice · 2021
18. A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myelomaLeukemia & lymphoma/Leukemia and lymphoma · 2021
19. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patientsSHILAP Revista de lepidopterología · 2021
20. Baseline serum B‐cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myelomaEuropean Journal Of Haematology · 2021